Research across Multiple Sclerosis
Related studies from across the Multiple Sclerosis family.
Serum neurofilament light chain serves as a robust biomarker of recent neuroaxonal injury in Multiple Sclerosis
Blood tests may help track nerve damage in Multiple Sclerosis
This guideline evaluates serum neurofilament light chain (sNfL) as a blood-based biomarker for multiple sclerosis. The evidence indicates sN…
A new blood marker called sNfL can help doctors see recent nerve damage and predict future disability risk in people with Multiple Sclerosis…
Diabetes mellitus acts as a context-dependent modifier of risk and phenotype in neurological disorders
Diabetes May Influence Risk and Progress of Neurological Disorders
This narrative review synthesizes evidence regarding the role of diabetes mellitus (DM) as a disease modifier across various neurological co…
New research suggests that diabetes can change how certain neurological conditions progress, potentially opening doors for new treatment opt…
NfL serves as a sensitive biomarker for RRMS progression while GFAP lacks independent prognostic value
Protein levels help predict multiple sclerosis relapses and disability
This meta-analysis of 4,016 individuals with multiple sclerosis evaluates NfL and GFAP as biomarkers for relapses and disability progression…
A specific protein called NfL can help doctors predict relapses and the worsening of physical disability in people with multiple sclerosis.
Aging impacts multiple sclerosis pathobiology by shifting inflammation toward chronic, compartmentalized neuroinflammation and neurodegeneration
New research explores how aging changes multiple sclerosis treatment
This narrative review examines the impact of aging on the immunological and neuroinflammatory microenvironment in older patients with multip…
As people age, multiple sclerosis can change from sudden flare-ups to a slow, steady progression of nerve damage.
Menopause does not appear to be a distinct clinical inflection point for multiple sclerosis progression
Menopause does not appear to be a turning point for MS
This narrative review examines the impact of menopause and biological aging on women with multiple sclerosis. The authors conclude that whil…
While menopause can make symptoms harder to manage, it is not a clear biological turning point for the progression of multiple sclerosis.
Nutrient and metabolite interventions for neurodegenerative diseases show inconsistent clinical translation
Dietary nutrients show mixed results for brain diseases in lab and early human data
This narrative review synthesizes evidence on nutrients and metabolites for Alzheimer's, Parkinson's, multiple sclerosis, and amyotrophic la…
Nutrients like vitamins and marine compounds show promise in labs, but human evidence for brain diseases remains inconsistent and unclear.
High-dose ocrelizumab 1200/1800 mg shows no significant difference in disability progression versus 600 mg in MS
High-dose ocrelizumab did not further reduce disability progression in multiple sclerosis patients
This phase 3b randomized controlled trial in 860 and 753 patients with relapsing or primary progressive multiple sclerosis found that high-d…
A large trial found that higher doses of ocrelizumab did not lower the risk of disability progression compared to the standard dose in multi…
Ocrelizumab reduces disability progression risk in primary progressive multiple sclerosis versus placebo
Ocrelizumab reduces disability risk for primary progressive multiple sclerosis patients
This phase 3b trial evaluated intravenous ocrelizumab versus placebo in patients with primary progressive multiple sclerosis. The study foun…
A large trial found ocrelizumab significantly lowers the risk of disability progression in patients with primary progressive multiple sclero…
T cell-microglial interactions drive aging and myelin changes in neurodegeneration models
Aging changes brain cells and invites immune cells that hurt nerve repair
This narrative review synthesizes evidence from murine models on T cell-microglial interactions in aging and neurodegeneration. It argues th…
Aging alters brain cell signals and brings in immune cells that damage myelin and stop nerve repair in mouse models.
NINJ1 targeting shows potential for multiple sclerosis and other neurological conditions but faces significant knowledge gaps
NINJ1 targeting shows promise for multiple sclerosis and other brain injuries
This narrative review examines NINJ1 targeting as a therapeutic strategy for multiple sclerosis, ischemic stroke, traumatic brain injury, sp…
A review suggests NINJ1 targeting could help treat multiple sclerosis, stroke, and other brain injuries, though more research is needed.
Narrative review discusses MS continuum concepts for high-risk individuals
New review suggests viewing MS as a continuum helps monitor those at higher risk
This narrative review addresses multiple sclerosis in individuals at higher risk for the condition. The authors argue that conceptualizing M…
A new review suggests that seeing multiple sclerosis as a continuous process could help doctors better monitor people at higher risk for the…
Ibudilast metabolomics in progressive multiple sclerosis brain atrophy trial
Metabolite levels linked to slower brain shrinkage in MS patients
This randomized trial in 244 participants with progressive multiple sclerosis evaluated oral ibudilast versus placebo over 96 weeks. Higher …
Higher baseline levels of certain metabolites were associated with slower brain shrinkage in people with progressive multiple sclerosis taki…